JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications
Authors' conclusion
JAKi were associated with a higher incidence of malignancy compared with TNFi but not placebo or methotrexate. Cancers were rare events in all comparisons.
Study context
- Population
- Adults with RA, PsA, psoriasis, axSpA, inflammatory bowel disease or atopic dermatitis in phase II/III/IV randomised clinical trials (RCTs) and long-term extension (LTE) studies, searched to December 202262 RCTs and 16 LTE studies
- Comparison
- Janus kinase inhibitors (JAKi) vs placebo, TNFi or MTX
- Outcome
- Incidence of malignancy (IRR)
Methodological detailsnetwork and pairwise meta-analyses, Cochrane Risk of Bias-2 tool
- Network and pairwise meta-analyses
- Cochrane Risk of Bias-2 tool
Pooled result
As reported in the abstract
All malignancies including NMSC (network meta-analysis)
Incidence rate ratio (95% CI)
JAKivs Placebo
0.71(0.44–1.15)
JAKivs MTX
0.77(0.35–1.68)
JAKivs TNFi
1.50(1.16–1.94)
- Overall malignancy incidence rate in RCTs (per 100 person-years)
- 1.15
- Overall malignancy incidence rate, combined RCT and LTE data (per 100 person-years)
- 1.26
Further pooled results
NMSC only; combined RCT/LTE data
- Findings consistent with the main analysis
Original publication
JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications. Ann Rheum Dis. Published 29 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →